e-learning
resources
London 2016
Monday, 05.09.2016
Clinical and molecular studies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Eric D. Bateman (Cape Town, South Africa), Eric D. Bateman, Alfredo Guerreros, Florian Brockhaus, Bjoern Holzhauer, Abhijit Pethe, Richard Kay, Robert G. Townley
Source:
International Congress 2016 – Clinical and molecular studies in asthma
Session:
Clinical and molecular studies in asthma
Session type:
Oral Presentation
Number:
1981
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Eric D. Bateman (Cape Town, South Africa), Eric D. Bateman, Alfredo Guerreros, Florian Brockhaus, Bjoern Holzhauer, Abhijit Pethe, Richard Kay, Robert G. Townley. Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy. Eur Respir J 2016; 48: Suppl. 60, 1981
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Safety and tolerability of acute dosing of beta-blockers in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013
Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Evaluation of methotrexate in the treatment of severe asthma
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA
Source: International Congress 2014 – Paediatric asthma: what is new for the clinician?
Year: 2014
Ultra-rush sublingual immunotherapy: Safety of use for patients with various allergic manifestations
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept